Trendlines Group Ltd. · SGX:42T
Trendlines — PregnanTech — Investor Presentation (July 2021)
19 slides from Trendlines's investor presentation, July 2021
Slide 1: Novel technology for the prevention of Preterm birth
Novel technology for the prevention of Preterm birth Company Overview
Slide 2: Background – Preterm birth (PTB)
Background – Preterm birth (PTB) Babies born Babies born at term preterm 37 - 42 weeks of pregnancy 23 - 37 weeks of pregnancy 2,500 – 4,000 grams 500 – 2,500 grams PregnanTech 2
Slide 3: Preterm Birth - Most common, catastrophic and costly pregnancy complication
Preterm Birth - Most common, catastrophic and costly pregnancy complication Prevalence • >1 in 10 babies WW [ WHO ] • 15M / Year of which 1M will die • 5 - 12% in developed countries • 6 – 18% in developing countries • USA: 10-12% of deliveries 500,000 / Year Rates have not changed for decades Pregn
Slide 4: Preterm Birth - Most common, catastrophic and costly pregnancy complication
Preterm Birth - Most common, catastrophic and costly pregnancy complication • Leading cause of global morbidity in children up to 5 years old • 25-50% of neurological impairments • Life long morbidity • Breathing & feeding disorders • Neural disabilities • Hearing loss • Blindness • Neurodevelopment
Slide 5: Preterm Birth Financial burden
Preterm Birth Financial burden • Average cost of newborn treatment x10 that of a baby born at term • $49,000 vs. $4500 at term • 47% of infant hospitalization costs • Financial burden: >$25.2B (USA) Delaying preterm birth by 1 week reduces hospitalization costs by >25% PregnanTech
Slide 6: Spontaneous Preterm Birth
Spontaneous Preterm Birth 60-70% of preterm births Contractions Internal An intervention situated os close to the internal os decreasing cervical loading will inhibit collagen network Biomechanical disruption and prevent cascade spontaneous preterm birth House M, et al. Ultrasound Inflammatory chang
Slide 7: Risk for spontaneous preterm birth
Risk for spontaneous preterm birth Twin History of Cervical Cervical Premature pregnancies preterm birth shortening insufficiency contractions 50 - 60% 35 - 45% 15 - 25% >50% w/o 35 - 45% cerclage 9-17% of all pregnancies are at risk PregnanTech 48
Slide 8: Existing Solutions – Unsatisfactory
Existing Solutions – Unsatisfactory Rates of preterm birth have not changed for decades Progesterone Tocolytic medications Cerclage suture Pessaries • Prophylactic daily or • Indication: Premature • Indication: Cervical • Causes retro flexion of weekly treatment contractions insufficiency cervix (Ar
Slide 9: Lioness
Lioness ‘s Lioness Game changing device for the prevention of preterm birth • Disposable silicone ring placed in the vagina high around the uterine cervix near the level of the internal os Ease of use • Placed by the physician in an outpatient setting • Few minute procedure • Aided by application to
Slide 10: Lioness: Efficient & Safe
‘s Lioness Efficient & Safe Efficacy • Non-surgical yet secured at site of best surgical procedure (Shirodkar cerclage) • Avoids cervical dilatations & shortening despite contractions • Reduces load and pressure on cervix • Delays the biomechanical cascade leading to preterm birth Safety • Self rele
Slide 11: a
a
Slide 12: Clinical trial First in Human safety study
Clinical trial First in Human safety study • Prospective, non randomized, open label, single arm study (ongoing) • Placement of Lioness for a period of up to 45d • 13 patients age 20-45 before hysterectomy due to benign indications • Follow-up every 3 – 7d for side effects • Macroscopic & microscopi
Slide 13: Milestones
Milestones Series A Round 2020 2021 2022 2023 H1 H2 H1 H2 H1 H2 H1 H2 Trial #1 Trial #2 Trial #3 Clinical studies Regulatory process #1 - Prehysterectomy safety and usability 2024 #2 - Pilot (10-20 participants) FDA Breakthrough devices track De-Novo pathway Pregnant women at risk of preterm birth #
Slide 14: Intellectual Property
Intellectual Property 2 Patent certifications All claims found allowable PregnanTech PregnanTech
Slide 15: Special endorsement
Special endorsement Most influential obstetrician in Europe “I believe it is important and necessary to test the safety, performance and efficacy of this device in pregnant women … I intend to lead and fund an acceptability trial of the device in a cohort of pregnant women and Prof. K. Nicolaides th
Slide 16: Begin sales in US
2024 2024 2025 Begin sales Begin sales Begin sales in US in EU in BRIC PregnanTech
Slide 17: Future additional indications of our technology
Future additional indications of our technology Digital health Drug application eluting Follow up of apparatus healthy pregnancies Progesterone Fetal well being Tocolytics Continuous fetal heart rate monitoring Prostaglandins Signaling in cases of fetal distress Additional information PregnanTech
Slide 18: Team
David Shashar Limor Sandach MD, Ob/Gyn, Chairwoman MBA, BME CEO Nir Lilach Nufar Bar-Or R&D Operations & manager clinical manager Team Steve Rhodes Buffy Alegria Prof. Eyal Schiff Director & FemTech Medical Business advisor advisor advisor
Slide 19: Take part in reducing the rate of preterm birth worldwide
Take part in reducing the rate of preterm birth worldwide Contact: Dr. David Shashar, CEO | David.Shashar@PregnanTech.com